A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

NCT04682431 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

127

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor business decision.

Conditions

Advanced Solid Tumor
Gynecologic Cancer
Breast Cancer
Colorectal Cancer
Gastric Adenocarcinoma
Lung Adenocarcinoma
Pancreatic Cancer
Head and Neck Cancer

Interventions

DRUG: PY159 Single agent dose level 1
DRUG: PY159 Single agent dose level 2
DRUG: PY159 Single agent dose level 3
DRUG: PY159 Single agent dose level 4
DRUG: PY159 Single agent dose level 5
DRUG: PY159 Single agent dose level 6
DRUG: PY159 Single agent dose level 7
DRUG: PY159/Pembrolizumab Combination dose level 1
DRUG: PY159/Pembrolizumab Combination dose level 2
DRUG: PY159/Pembrolizumab Combination dose level 3
DRUG: PY159/Pembrolizumab Combination dose level 4
DRUG: PY159 Single agent dose expansion cohort
DRUG: PY159/Pembrolizumab Combination dose expansion cohort 1
DRUG: PY159/Pembrolizumab Combination dose expansion cohort 2
DRUG: PY159/Pembrolizumab Combination dose expansion cohort 3
DRUG: PY159/Pembrolizumab Combination dose expansion cohort 4
DRUG: PY159/Pembrolizumab Combination dose expansion cohort 5
DRUG: PY159/Pembrolizumab Combination dose expansion cohort 6

Sponsor

Ikena Oncology